Table 2 Baseline characteristics between Normal uric acid group and hyperiuricemia
Independent variable | Normal uric acid group | hyperuricemia group | P |
|---|---|---|---|
Number | 68 | 34 | - |
Age | 36.6±9.02 | 33.44±7.67 | 0.078 |
rum uric acid,mg/dl | 5.79±0.97 | 8.27±0.97 | - |
HLA–B27 positive, no. (%) | 63 (92.65) | 32 (94.12) | 0.782 |
Symptom duration, years | 11.42±8.89 | 10.91±6.54 | 0.757 |
History of uveitis, no. (%) | 8 (11.76) | 3 (8.82) | 0.652 |
History of psoriasis, no. (%) | 0 (0) | 0 (0) | - |
History of IBD, no. (%) | 2 (1.96) | 0 (0) | - |
History of peripheral arthritis, no. (%) | 11 (16.17) | 5 (14.71) | 0.8 |
csDMARDs use, no. (%) | 41 (64.06) | 19 (55.89) | 0.67 |
NSAID use, no. (%) | 38 (59.375) | 21 (61.18) | 0.57 |
TNFi use, no. (%) | 15 (22.06) | 8 (23.53) | |
outcome | |||
PtGA，0–100 | 20.02±20 | 13.52±15.58 | 0.075 |
Spinal pain ,0–100 | 16.69±16.1 | 11.91±13.18 | 0.114 |
Spinal pain in ninght,0–100 | 14.82±16.85 | 10.38±14.54 | 0.173 |
BASDAI,0–10 | 1.58±1.42 | 1.07±0.92 | 0.031 |
BASFI,0–10 | 0.63±0.9 | 0.55±1.08 | 0.692 |
ASDAS-CRP | 1.38±0.79 | 1.17±0.65 | 0.164 |
SF-36:PF (Physical Functioning) | 87.27±14.62 | 88.38±14.34 | 0.523 |
SF-36:RP (Role-Physical) | 74.26±38.86 | 63.23±43.62 | 0.206 |
SF-36:BP (Bodily Pain) | 72.63±14.11 | 74.17±12.87 | 0.421 |
SF-36:GH (General Health) | 58.3±19.44 | 56.32±18.17 | 0.527 |
SF-36:VT (Vitality) | 67.13±12.67 | 60.14±15.19 | 0.019 |
SF-36:SF (Social Functioning) | 89.33±18.35 | 90.44±18.47 | 0.74 |
SF-36:RE (Role-Emotional) | 73.52±38 | 72.54±38.89 | 0.891 |
SF-36:MH (Mental Health) | 50.35±13.99 | 50.47±14.43 | 0.853 |
CRP (mg/liter) | 5.26±7.24 | 4.54±5.13 | 0.763 |
ESR (mm/h) | 9.71±10.75 | 11.08±9.62 | 0.16 |